Pay in 4 interest-free payments of $25.00 Learn more
Ships within 48 hours · Estimated delivery Jul 26 - Jul 31
K562 cells) treatment inhibits MAPK/ERK/JNK downstream signaling and diminishes Jak2/Stat3/Akt expression
BI-4020 - CAS# 2664214-60-0 mfenac D5 Sodium Hydrate K562 cells) treatment inhibits MAPK/ERK/JNKBI 4020 is a fourth generation, orally active, and non covalent EGFR tyrosine kinase inhibitor. BI 4020 inhibits not only the triple mutant EGFR del19 T790M C797S variant (IC50=0. 2 nM in BaF3 cell lines) but also the double mutant EGFR del19 T790M and primary mutant EGFR del19 (IC50=1 nM). BI 4020 also shows activity against EGFR wt (IC50=190 nM). BI 4020 shows high kinome selectivity and good DMPK properties. Product information CAS Number: 2664214
US$ 139.00
US$ 69.00
US$ 12.00
US$ 29.00
US$ 22.00
US$ 99.00